A clinical trial involving insulin lispro was updated on September 25, 2026, according to ClinicalTrials.gov records. The study, titled "Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia," is registered under identifier NCT05748990.
The trial's current status is listed as active, not recruiting. Its phase is designated as not applicable in the registry. This status indicates that participant enrollment is not currently open, though the study is ongoing.
No results have been posted for this trial in the data reviewed. The event data does not include information on outcomes, findings, or conclusions related to insulin's role in cognitive or metabolic function in schizophrenia. This brief reports only the trial's registration status and title as recorded.
Insulin lispro is an approved compound. This update reflects a change in trial recruitment status only and does not represent new efficacy or safety data. Readers seeking further trial details can consult the ClinicalTrials.gov listing directly.
For more background on this compound, see the compound overview linked with this brief.